Orchestra BioMed
OBIO
51 hedge funds and large institutions have $124M invested in Orchestra BioMed in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
11% more funds holding
Funds holding: 46 → 51 (+5)
2.67% more ownership
Funds ownership: 56.84% → 59.51% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $130M → $124M (-$6.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
+$3.11M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.64M |
| 3 |
GL
Governors Lane
New York
|
+$2.59M |
| 4 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$812K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$776K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.79M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.07M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.12M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$560K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$539K |
OBIO Hedge Fund Activity: Q2 2021 in Review
51 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2021, worth a combined $124M — down 4.7% from $130M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OBIO positions and 3 closed out — a net gain of 5 holders — while 12 added to existing stakes and 9 trimmed.
The largest buyer was Davidson Kempner Capital Management, adding an estimated $3.11M. The largest seller was Cormorant Asset Management, cutting an estimated $5.79M.
- 51 institutional investors held Orchestra BioMed (OBIO) as of Q2 2021, up from 46 in Q1 2021.
- Funds reported $124M of Orchestra BioMed stock for Q2 2021, down 4.7% quarter-over-quarter.
- 8 funds opened new Orchestra BioMed positions in Q2 2021 and 3 closed out, a net change of +5 holders.
- The largest Orchestra BioMed buyer in Q2 2021 was Davidson Kempner Capital Management, an estimated $3.11M added.
- The largest Orchestra BioMed seller in Q2 2021 was Cormorant Asset Management, an estimated $5.79M sold.
Based on aggregated 13F filings for Q2 2021.